Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.
Looking for a particular Epigenomics AG employee's phone or email?
Epigenomics AG Questions
The Epigenomics AG annual revenue was $6.6 million in 2026.
Michael Wandell is the Senior Vice President, Clinical, Regulatory and Quality of Epigenomics AG.
19 people are employed at Epigenomics AG.
Epigenomics AG is based in San Diego, California.
The NAICS codes for Epigenomics AG are [62151, 621, 54, 541, 62, 5417, 54171, 541712, 6215].
The SIC codes for Epigenomics AG are [87, 873].
Top Epigenomics AG Employees
-
12 -
Mike Wardell
Senior Vice President, Clinical, Regulatory and quality at Epigenomics AG
Mercer Island, WA, US1 -
Michael Wandell
Senior VP Clinical Regulatory Quality at Epigenomics AG
Mercer Island, WA, US2 -
Albert Grey
Area Business Manager at Epigenomics AG
New York, United States35 -
Kenneth Wong
Senior Scientist at Epigenomics AG
Encinitas, CA, US22 -
Stefanie Kasielke
Research Scientist at Epigenomics AG
Hamburg, HH, DE1
Related Companies
